Case Report: Case series: growth hormone replacement for severe growth hormone deficiency during BRAF inhibitor therapy in pediatric low-grade glioma: long-term follow-up
7 affiliations
- 1Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa
- 2Neuro-Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini
- 3Pediatric Gastroenterology and Endoscopy Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini
- 4Department of Woman and Child, ASST-Settelaghi, University of Insubria
- 5Neuroradiology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini
- 6Pharmacy, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini
- 7Pediatric Clinic, Endocrinology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Giannina Gaslini
Abstract
Pediatric low-grade gliomas (pLGGs) involving the hypothalamic-pituitary region frequently result in endocrine dysfunction, particularly growth hormone deficiency (GHD), due to tumor location and treatment-related effects. Growth hormone replacement therapy (GHRT) is generally considered after a period of disease stability, whereas its use during active oncologic therapy remains controversial, including during BRAF inhibitor (BRAFi) treatment. We describe two pediatric patients with severe GHD who received GHRT during ongoing vemurafenib, a BRAFi, for progressive chiasmatic-hypothalamic pLGG. The first patient, a girl diagnosed in infancy with desmoplastic infantile ganglioglioma, developed severe GHD after biopsy, chemotherapy, partial tumor debulking, and targeted therapy, together with multiple additional endocrine deficiencies. The second patient, a boy with pilocytic astrocytoma, was diagnosed with severe GHD after multimodal treatment, including partial and subtotal surgical resections, chemotherapy, radiotherapy, and targeted therapy. In both cases, low-dose GHRT was initiated after multidisciplinary assessment, documented radiological stability before GHRT initiation, and family counseling regarding the absence of direct safety data during active BRAFi therapy. Treatment was titrated over two months, with regular IGF-1 monitoring and close endocrine and oncologic surveillance. During approximately six years of concomitant GHRT and vemurafenib exposure, growth stabilized and lipid parameters improved, whereas catch-up growth remained limited and bone outcomes were complex, with increased bone mineral content but persistent or worsening lumbar DXA-derived impairment. No tumor progression or secondary malignancies were detected during the reported follow-up. These two cases add to the limited evidence on GHRT administration during BRAFi therapy by documenting prolonged concomitant GHRT and vemurafenib exposure in children with severe confirmed GHD and previously progressive chiasmatic-hypothalamic pLGG. However, the limited sample size and observational nature of this report preclude conclusions about safety or efficacy. Larger prospective studies are needed to define which patients may benefit and under which monitoring conditions GHRT could be considered during BRAFi therapy.
Related
- Editorial: Long-acting growth hormone therapy in pediatric growth hormone deficiency
- How healthcare professionals manage uncertainty around hormone replacement therapy (dis-)continuation: the TAPER qualitative Study
- Hormone Replacement Therapy and Disability Progression in Women with Multiple Sclerosis
- The Effects of Estrogen-Based Hormone Replacement Therapy on Women Aged ≥55 Years Undergoing 1- to 3-Level Posterior Lumbar Spinal Fusion Surgery
- Glucocorticoid replacement therapy and anthropometric features in patients with 21-hydroxylase deficiency in Japan: results from a nationwide epidemiological study
BibTeX
@article{panciroli2026case,
title = {{Case Report: Case series: growth hormone replacement for severe growth hormone deficiency during BRAF inhibitor therapy in pediatric low-grade glioma: long-term follow-up}},
author = {Marta Panciroli and Antonio Verrico and Marco Crocco and Sara Cencioni and Chiara Morreale and Antonia Ramaglia and Valentina Iurilli and Gianluca Piccolo and Claudia Milanaccio and Mohamad Maghnie and Natascia Di Iorgi},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1940850},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1940850/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case Report: Case series: growth hormone replacement for severe growth hormone deficiency during BRAF inhibitor therapy in pediatric low-grade glioma: long-term follow-up
AU - Marta Panciroli
AU - Antonio Verrico
AU - Marco Crocco
AU - Sara Cencioni
AU - Chiara Morreale
AU - Antonia Ramaglia
AU - Valentina Iurilli
AU - Gianluca Piccolo
AU - Claudia Milanaccio
AU - Mohamad Maghnie
AU - Natascia Di Iorgi
PY - 2026
DA - 2026/10/08
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1940850
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1940850/full
AB - Pediatric low-grade gliomas (pLGGs) involving the hypothalamic-pituitary region frequently result in endocrine dysfunction, particularly growth hormone deficiency (GHD), due to tumor location and treatment-related effects. Growth hormone replacement therapy (GHRT) is generally considered after a period of disease stability, whereas its use during active oncologic therapy remains controversial, including during BRAF inhibitor (BRAFi) treatment. We describe two pediatric patients with severe GHD who received GHRT during ongoing vemurafenib, a BRAFi, for progressive chiasmatic-hypothalamic pLGG. The first patient, a girl diagnosed in infancy with desmoplastic infantile ganglioglioma, developed severe GHD after biopsy, chemotherapy, partial tumor debulking, and targeted therapy, together with multiple additional endocrine deficiencies. The second patient, a boy with pilocytic astrocytoma, was diagnosed with severe GHD after multimodal treatment, including partial and subtotal surgical resections, chemotherapy, radiotherapy, and targeted therapy. In both cases, low-dose GHRT was initiated after multidisciplinary assessment, documented radiological stability before GHRT initiation, and family counseling regarding the absence of direct safety data during active BRAFi therapy. Treatment was titrated over two months, with regular IGF-1 monitoring and close endocrine and oncologic surveillance. During approximately six years of concomitant GHRT and vemurafenib exposure, growth stabilized and lipid parameters improved, whereas catch-up growth remained limited and bone outcomes were complex, with increased bone mineral content but persistent or worsening lumbar DXA-derived impairment. No tumor progression or secondary malignancies were detected during the reported follow-up. These two cases add to the limited evidence on GHRT administration during BRAFi therapy by documenting prolonged concomitant GHRT and vemurafenib exposure in children with severe confirmed GHD and previously progressive chiasmatic-hypothalamic pLGG. However, the limited sample size and observational nature of this report preclude conclusions about safety or efficacy. Larger prospective studies are needed to define which patients may benefit and under which monitoring conditions GHRT could be considered during BRAFi therapy.
SN - 1664-2392
ER -